Document is current
Any future updates will be listed below
-
Authors
Shah, Shrey B.
Peddada, Teja N.
Song, Christopher
Mensah, Maame
Sung, Heejong
Yavi, Mani
Yuan, Peixiong
Zarate, Carlos A. Jr
Mickey, Brian J.
Burmeister, Margit
Akula, Nirmala
McMahon, Francis J.
-
Funding
Funding for this research was provided by:
National Institute of Mental Health (ZIA-MH002844, ZIA-MH002844, ZIA-MH002844, ZIA-MH002844, ZIA-MH002844, K23-MH092648, K23-MH092648, K23-MH092648, ZIA-MH002844, ZIA-MH002844)
National Center for Advancing Translational Sciences (2UL1 TR000433, 2UL1 TR000433)
The Taubman Medical Research Institute
The University of Michigan Depression Center
- License Information
-
More Information
Article History
Received: 25 March 2023
Accepted: 18 July 2023
First Online: 1 August 2023
Competing interests
: Dr. Carlos A. Zarate, Jr. is a full-time U.S government employee. He is listed as a coinventor on a patent for the use of ketamine in major depression and suicidal ideation. Dr. Zarate is listed as a coinventor on a patent for the use of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain. Dr. Zarate is listed as co-inventor on a patent application for the use of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation and post-traumatic stress disorders. Dr. Zarate has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. All other authors declare no competing interests.
